Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Mason Osann, Emily ^a,c   Hollevoet, Kevin ^a,d   Niederfellner, Gerhard ^b   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ROCHE INNOVATION CENTER MUNICH   (Germany)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALEXA FLUOR 647; ANTIBODY CONJUGATE; CARBOCYANINE; RG7787;

ANIMAL; APOPTOSIS; CHEMISTRY; DOSE CALCULATION; DRUG EFFECTS; FEMALE; FLUORESCENCE MICROSCOPY; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; APOPTOSIS; CARBOCYANINES; CELL LINE, TUMOR; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; IMMUNOCONJUGATES; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; PANCREATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84933564866     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10832     Document Type: Article

References (31)

1. Weldon, J. E. & Pastan, I. A guide to taming a toxin-recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J. 278, 4683-4700 (2011
2. Li, G. N., Wang, S. P., Xue, X., Qu, X. J. & Liu, H. P. Monoclonal antibody-related drugs for cancer therapy. Drug Discov. Ther. 7, 178-184 (2013
3. Minchinton, A. I. & Tannock, I. F. Drug penetration in solid tumours. Nat. Rev. Cancer 6, 583-592 (2006
4. Christiansen, J. & Rajasekaran, A. K. Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol. Cancer Ther. 3, 1493-1501 (2004
5. Shin, T. H, et al. Enhancement of the tumor penetration of monoclonal antibody by fusion of a neuropilin-Targeting peptide improves the antitumor efficacy. Mol. Cancer Ther. 13, 651-661 (2014
6. Heine, M, et al. High interstitial fluid pressure is associated with low tumour penetration of diagnostic monoclonal antibodies applied for molecular imaging purposes. PloS One 7, e36258 (2012
7. Chauhan, V. P, et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat. Nanotechnol. 7, 383-388 (2012
8. Juweid, M, et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 52, 5144-5153 (1992
9. Rudnick, S. I, et al. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res. 71, 2250-2259 (2011
10. Hassan, R, et al. 111Indium-labeled monoclonal antibody K1: biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin. Int. J. Cancer 80, 559-563 (1999
11. Pastuskovas, C. V, et al. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol. Cancer Ther. 11, 752-762 (2012
12. Wang, S, et al. Pulsed high intensity focused ultrasound increases penetration and therapeutic efficacy of monoclonal antibodies in murine xenograft tumors. J. Control Release 162, 218-224 (2012
13. Hollevoet, K, et al. In vitro and in vivo activity of the low-immunogenic anti-mesothelin immunotoxin RG7787 in pancreatic cancer. Mol. Cancer Ther. In Press PMID 2492849 (2014
14. Hassan, R, et al. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci. Transl. Med. 5, 208ra147 (2013
15. Ho, M, et al. Mesothelin expression in human lung cancer. Clin. Cancer Res. 13, 1571-1575 (2007
16. Pastan, I. & Hassan, R. Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res. 74, 2907-2912 (2014
17. Liu, W, et al. Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc. Natl. Acad. Sci. USA 109, 11782-11787 (2012
18. Weldon, J. E, et al. A recombinant immunotoxin against the tumor-Associated antigen mesothelin reengineered for high activity, low off-Target toxicity, and reduced antigenicity. Mol. Cancer Ther. 12, 48-57 (2013
19. Zhang, Y, et al. A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake. Cancer Res. 70, 1082-1089 (2010
20. Chan, K. T, et al. Overexpression of transferrin receptor CD71 and its tumorigenic properties in esophageal squamous cell carcinoma. Oncol. Rep. 31, 1296-1304 (2014
21. Ryschich, E, et al. Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas. Eur. J. Cancer 40, 1418-1422 (2004
22. Gatter, K. C., Brown, G., Trowbridge, I. S., Woolston, R. E., & Mason, D. Y. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J. Clin. Pathol. 36, 539-545 (1983
23. Prost, A. C, et al. Differential transferrin receptor density in human colorectal cancer: A potential probe for diagnosis and therapy. Int. J. Oncol. 13, 871-875 (1998
24. Lloyd, J. M., ODowd, T., Driver, M. & Tee, D. E. Demonstration of an epitope of the transferrin receptor in human cervical epithelium-A potentially useful cell marker. J. Clin. Pathol. 37, 131-135 (1984
25. Daniels, T. R., Delgado, T., Rodriguez, J. A., Helguera, G. & Penichet, M. L. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin. Immunol. 121, 144-158 (2006
26. Magro, G, et al. Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target. Thyroid 21, 267-277 (2011
27. Han, J., Wang, Q., Zhang, Z., Gong, T. & Sun, X. Cationic bovine serum albumin based self-Assembled nanoparticles as siRNA delivery vector for treating lung metastatic cancer. Small 10, 524-535 (2014
28. Yewale C., Baradia, D., Vhora, I. & Misra, A. Proteins: emerging carrier for delivery of cancer therapeutics. Expert Opin. Drug Deliv. 10, 1429-1448 (2013
29. Provenzano, P. P, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21, 418-429 (2012
30. Stromnes, I. M., DelGiorno, K. E., Greenberg, P. D. & Hingorani, S. R. Stromal reengineering to treat pancreas cancer. Carcinogenesis 35, 1451-1460 (2014
31. Pak, Y., Zhang, Y., Pastan, I. & Lee, B. Antigen shedding may improve efficiencies for delivery of antibody-based anticancer agents in solid tumors. Cancer Res. 72, 3143-3152 (2012